Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure: Journal of Hepatology

NAVIGATORE-Lombardia and Veneto Study Groups, E. Degasperi, A. Spinetti, A. Lombardi, S. Landonio, M.C. Rossi, L. Pasulo, P. Pozzoni, A. Giorgini, P. Fabris, A. Romano, L. Lomonaco, M. Puoti, M. Vinci, F. Gatti, G. Carolo, A. Zoncada, P. Bonfanti, F.P. Russo, A. AghemoA. Soria, R. Centenaro, F. Maggiolo, P. Rovere, F. Pasin, V. Paon, G. Faggiano, A. Vario, G. Grossi, R. Soffredini, C. Carriero, S. Paolucci, F. Noventa, A. Alberti, P. Lampertico, S. Fagiuoli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1106-1115
Number of pages10
JournalJ. Hepatol.
Volume71
Issue number6
DOIs
Publication statusPublished - 2019

Keywords

  • Direct-acting antivirals
  • HCV
  • RAS
  • Resistance
  • Retreatment
  • Sofosbuvir

Cite this

NAVIGATORE-Lombardia and Veneto Study Groups, Degasperi, E., Spinetti, A., Lombardi, A., Landonio, S., Rossi, M. C., ... Fagiuoli, S. (2019). Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure: Journal of Hepatology. J. Hepatol., 71(6), 1106-1115. https://doi.org/10.1016/j.jhep.2019.07.020